Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Current Assets (2023 - 2025)

Contineum Therapeutics (CTNM) has 3 years of Current Assets data on record, last reported at $184.9 million in Q3 2025.

  • For Q3 2025, Current Assets fell 14.04% year-over-year to $184.9 million; the TTM value through Sep 2025 reached $184.9 million, down 14.04%, while the annual FY2024 figure was $206.4 million, 61.61% up from the prior year.
  • Current Assets reached $184.9 million in Q3 2025 per CTNM's latest filing, up from $176.8 million in the prior quarter.
  • Across five years, Current Assets topped out at $220.3 million in Q2 2024 and bottomed at $119.7 million in Q1 2024.
  • Average Current Assets over 3 years is $180.4 million, with a median of $188.5 million recorded in 2025.
  • Peak YoY movement for Current Assets: skyrocketed 61.61% in 2024, then dropped 19.74% in 2025.
  • A 3-year view of Current Assets shows it stood at $127.7 million in 2023, then surged by 61.61% to $206.4 million in 2024, then dropped by 10.4% to $184.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Assets were $184.9 million in Q3 2025, $176.8 million in Q2 2025, and $192.1 million in Q1 2025.